

A graphic featuring two hands shaking in a firm grip, symbolizing agreement or partnership. The hands are rendered in a semi-transparent, blue-tinted style. Overlaid on the hands is a world map, with the continents appearing as dark blue shapes against a lighter blue background. The map is centered on the Atlantic Ocean. The entire graphic is set against a dark blue background with a diagonal white line running from the top left to the bottom right. A large, solid blue triangle is positioned in the bottom left corner, partially overlapping the white line.

THE COVAX FACILITY

GLOBAL COLLABORATION



- The need
 - Accelerate the development and manufacture of COVID-19 vaccines, diagnostics and treatments
 - Guarantee rapid, fair and equitable access to all countries
- Governments, health organizations, scientists, businesses, civil society, and philanthropists.....
 - Joined forces to speed up efforts to end the pandemic

COVAX FACILITY

- Established April 2020
- COVAX - COVID-19 Vaccine Global Access (COVAX) Facility
 - WHO / PAHO
 - UNICEF
 - World Bank
 - Global Alliance for Vaccines and Immunizations (GAVI) Secretariat
 - Coalition for Epidemic Preparedness Innovations (CEPI)



COVAX FACILITY CONT'D

- The COVAX Facility pools purchasing power
 - Speak to the manufacturers - USD 8.70-37.00
 - Negotiate best price
 - Estimated price possibly US\$10 - \$20 per dose
 - There may be tiered pricing or one single flat price



COVAX FACILITY CONT'D



- Diversified portfolio across different technologies, geographies and vaccine characteristics
- Inclusion of candidates are based on:
 - Assessment by COVAX advisory committees
 - Joint tender for procurement and supply agreements by UNICEF / PAHO

COVAX FACILITY CONT'D

- Candidates are assessed on
 - Efficacy
 - Probability of success
 - Safety and immunogenicity
 - Availability of supply
 - Regional scope & scalability
 - Programmatic feasibility
 - Delivery considerations
 - Timing of doses
 - Pricing



COVAX FACILITY CONT'D

- The Facility continually monitors the COVID-19 vaccine landscape
- Identifies the most suitable vaccine candidates
 - Based on scientific merit and scalability



COVAX CONT'D

Commitment

- Provide at least **2 billion doses** by the end of 2021
- 500 million doses have been secured for Q1 and Q2
- End the acute phase of the pandemic by end of 2021
- Guarantee vaccine access to every participating country



COVAX OFFER UPTAKE

- All countries were invited to participate
 - 190 (Jan 2021)
- Countries participating in the Facility benefit from the assurance that the Facility can supply them with enough vaccine doses to immunize 20% of their country's population
- Receive vaccines at the negotiated price



COVAX OFFER UPTAKE CONT'D



Americas

- PAHO Revolving Fund (RF) are being represented as a unified “bloc” in the Facility
- RF mechanism is recognized as a viable procurement channel
- All vaccines will be PAHO/WHO prequalified
 - Reviewed and sanctioned by the various expert advisory groups

INDEMNITY

- Countries are required to sign indemnification agreement before vaccines will be issued through the COVAX Facility
- Vaccines may be available approximately 6-8 weeks after




INDEMNITY CONT'D


- USA
 - Legislative immunity to manufacturers
 - No one can bring a claim against the manufacturer
 - Alternate compensation method in place



VACCINE LANDSCAPE

As at 22 January





Technology	Attributes			
	Single dose	Already licensed technology	Speed of scale production	Current production scale
Inactivated virus	No	Yes	Medium	Medium/high
Attenuated virus	Yes	Yes	Slow	High
DNA-based	No	No	Fast	Medium
RNA-based	No	No	Fast	Low/medium
Viral vector	Maybe	Yes*	Medium	High
Protein-based	No	Yes	Medium/Fast	High

VACCINE LANDSCAPE CONT'D

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	20	31%
VVnr	Viral Vector (non-replicating)	10	16%
DNA	DNA	8	13%
IV	Inactivated Virus	9	14%
RNA	RNA	7	11%
VVr	Viral Vector (replicating)	4	6%
VLP	Virus Like Particle	2	3%
VVr + APC	VVr + Antigen Presenting Cell	2	3%
LAV	Live Attenuated Virus	1	2%
VVnr + APC	VVnr + Antigen Presenting Cell	1	2%
		64	

AstraZeneca

- Several manufacturers
- Indemnity forms required for each manufacturer
- 50 million doses will be available in Feb & Mar
Another 100 million doses available for delivery in Q2 2021
- 90 million additional doses from SII in Q1 2021, with another 150 million doses anticipated to become available in Q2 2021



OTHER VACCINES

Second half of 2021

- Single dose Johnson & Johnson/Janssen vaccine
- Novavax from multiple producers
- Sanofi/GSK
- Sinopharm



DNA / mRNA

Viral vectors

Protein-based

Inovio INO-4800	Moderna mRNA-1273	CureVac CVnCoV	Merck / Themis V591	AstraZeneca ChAdOx1-S	U. of Hong Kong	Novavax NVX- CoV2373	Clover SCB-2019
USA	USA	Germany	USA / Austria	UK	China	USA	China
Full-length S protein	Full-length S protein	Full-length S protein	Full-length S protein	Full-length S protein	Receptor Binding Domain / AS03	Full-length S protein / saponin-based Matrix-M	Full-length S protein/AS03 or CPG1018
Phase I/II	Phase III	Phase II	Phase I	Phase III	Pre-clinical	Phase III	Phase I



Speed



Scale



Acc

NEW WAVE

- Expedited supply
- Pfizer vaccine now being offered through the COVAX Facility
- Available in February



JAMAICA



AGREEMENT

- Government of Jamaica signed a commitment agreement with GAVI Alliance
 - Self financing
- Vaccinate 16% of our population in Phase 1
 - 935,676 doses
- Cost of USD10.55



NEXT STEPS

- Indemnification
- WHO/PHAO prequalification
- Acceptance of the Price Estimate
 - 6-8 weeks
- Arrears to the RF honored



VACCINE ARRIVAL

- 146,400-249,600 doses in February/March
- 65-75% in Q2





Thank You

